Prospective Case Collection Study of Contrast-Enhanced Mammography Imaging Acquired on a New Investigational Device
- Conditions
- Breast Screening
- Interventions
- Device: CEM Exam in Investigational Device
- Registration Number
- NCT06636539
- Lead Sponsor
- Hologic, Inc.
- Brief Summary
This is a prospective, single-center image case collection study to acquire de-identified contrast-enhanced breast images on the Investigational Device to support continuing technology development. Eligible subjects include women at least 35 years old with a suspicious finding or breast abnormality on a screening or diagnostic mammogram who are indicated for a diagnostic exam or a biopsy procedure.
- Detailed Description
Contrast-Enhanced Mammography (CEM) is intended to be an extension for diagnostic mammography with the Investigational Device. It is a technique in which digital 2D mammography is supplemented with the use of intravenous iodinated contrast administration to facilitate cancer detection. The imaging acquired under a contrast agent has preferential uptake in regions of increased vascularity providing complement information for diagnosis. The CEM software application that will be tested is similar to the marketed software I-View™ 2.0 and is intended for use as an adjunct following mammography and/or ultrasound exams as a diagnostic work-up to localize and further characterize a known or suspected lesion.
Thus, to assess the clinical efficacy of the CEM imaging acquired in the Investigational Device, Sponsor is conducting a prospective case collection study to support the verification and validation of image quality assessments.
Recruitment & Eligibility
- Status
- RECRUITING
- Sex
- Female
- Target Recruitment
- 75
- Subject is female of any race and ethnicity.
- Subject is at least 35 years old
- Subject has a suspicious finding or breast abnormality on a screening or diagnostic mammogram and is indicated for a diagnostic exam or a biopsy procedure.
- Subject is able to read, understand, and sign the study-specific informed consent form (ICF) after the nature of the study has been fully explained to them
- Subject is unable or unwilling to undergo informed consent or subject who requires a Legally Authorized Representative (LAR) for Informed Consent.
- Subject has breast implants, cardiac pacemakers, nipple piercings, or IV ports in the mammography field of view in the breast of interest.
- Subject has had an interventional procedure in the same breast as the suspicious finding within the last six (6) months
- Subject is pregnant or presumed to be pregnant.
- Subject is breastfeeding.
- Subject is actively being treated for cancer of any type with chemotherapy
- Subject is suspected to be at risk of complications from the iodinated contrast agent. These include contra-indications of standard iodinated contrast agents, such as the subject having renal insufficiency) and the subject being on dialysis.
- Subject has had a prior reaction to iodinated contrast; thus, a known allergy to iodinated contrast.
- Subject has had a prior reaction to gadolinium contrast agents; thus, a known allergy to gadolinium contrast.
- Subject who, based on the physician's judgment, may be at increased risk for complications associated with renal function, anticoagulant therapy, or bleeding disorders.
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Arm && Interventions
Group Intervention Description CEM Investigational Exam CEM Exam in Investigational Device All subjects enrolled in this study will undergo a CEM exam using Investigational Device
- Primary Outcome Measures
Name Time Method Obtain de-identified contrast-enhanced breast images on the Investigational Device. 4 months To obtain a minimum of 10 de-identified contrast-enhanced breast images with lesions to allow for image quality assessment.
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (1)
Solis Mammography Memorial Village
🇺🇸Houston, Texas, United States